Aura Biosciences, Inc. (AURA)

NGM – Real Time Price. Currency in USD

6.27

-0.17 (-2.64%)

At close: Mar 27, 2026, 4:00 PM EDT

6.28

+0.01 (0.16%)

After-hours: Mar 27, 2026, 5:56 PM EDT

About the company

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette–guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Key Executives

Name	Position
Dr. Anthony Daniels M.D.	VP & Therapeutic Area of Head Ocular Oncology
Dr. Elisabet de los Pinos Ph.D.	Founder, CEO, President & Director
Dr. Jill J. Hopkins M.D.	Chief Medical Officer & President of Research and Development
Dr. Mark Plavsic D.V.M., Ph.D.	Chief Technology Officer
Dr. Sabine Brookman-May	Senior VP & Therapeutic Area Head of Urologic Oncology
Mr. Conor Kilroy	Chief Legal Officer & Secretary
Mr. Patrick Nealon	Senior Vice President of Clinical Development Operations